New investigational data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show clinical activity in various leukemia subtypes driven...

New data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show promising clinical activity across a wide range of potentially...

– Nuvisertib (TP-3654), an oral investigational highly selective PIM-1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – MARLBOROUGH, Mass.,...

Rodney Peete joins the Time to Go™ campaign as the newest GEMTESA Go-Getter, alongside wife Holly Robinson Peete, encouraging men and women to speak up about their overactive bladder symptoms...

– Nuvisertib (TP-3654), an investigational highly selective oral PIM1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – – Nuvisertib...

MONTREAL and MARLBOROUGH, Mass., June 5, 2025 – Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”

– Data include results from COURAGE Phase 3 and COMPOSUR Phase 4 studies of vibegron (GEMTESA®) – MARLBOROUGH, Mass., April 29, 2025 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA)...

– Data includes extension study results for vibegron in patients with overactive bladder (OAB) while being pharmacologically treated for benign prostatic hyperplasia (BPH), and real-world...

– Partnership with the NCI will build on the promising preliminary clinical activity of enzomenib in acute leukemia to further explore potential activity in other cancers – MARLBOROUGH, Mass.,...

– GEMTESA® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – MARLBOROUGH, Mass., Dec. 23, 2024...